Ronjon Nag on Investment in the Longevity Industry

Ronjon Nag is a noted angel investor in the Bay Area, and one of the newer entries to the select community of investors interested in the longevity industry. He brings his own perspective to the table; new points of view are always welcome as the community grows in size, and as more narrowly focused specialists begin to emerge. That said, given the enormous venture funding still in waiting, looking for places to invest, there is always the perverse incentive for fund managers to consider the space of aging and longevity in the broadest sense possible. There is a pressure to invest now, invest soon, find more deals to participate in. This leads one to invest in what might be profitable ventures, but ventures that do nothing to help address aging, and are only engaged in some form of compensation for aging. Eldercare, supportive services, tools to help people who have lost function. I expect many funding institutions to lose their way in this fashion.

These are, of course, interesting times for investors, to say the least: we are amidst something of a hysteria regarding all things viral, and also in the opening weeks of a bear market that is long overdue and thus likely to be more unpleasant than usual. If one had to invest somewhere under the present circumstances, there are certainly worse options than a preclinical biotech company working on new therapies, however. Such a company is essentially immune to the vagaries of the broader market at any time other than when it has to raise funds. For much of its life, it keeps to itself, carries out its research, and engages with regulators rather than customers. The opening weeks of a crash are a great time to provide the funds for a biotech company to carry out a year or two of work. By the time the company is ready for the next step and the next round of fundraising, the market will have turned around.

Talking Longevity investment and risk with Ronjon Nag

We understand that you're looking at longevity as a dedicated investment category - what are the main differences you see to regular healthcare investing?

We look at longevity in the widest sense. In addition to biotech there could be investments in areas such as lifelong learning, fintech for the aged, and work opportunity platforms for the aging workforce. Cutting across these themes, we like to see a computational element and the application of artificial intelligence and data-mining within these companies. I tend to agree that this is a new space that will develop as a pure play over the next few years - both in terms of understanding the landscape and having enough quality targets to invest in. I look at artificial intelligence, longevity, and healthcare and cover all those segments to have enough vehicles to invest in.

You've helped over 50 companies secure funding - what are you looking for in new start-ups?

Firstly, we typically like to invest very early, at the seed or pre-stage stage, often being among the first to write checks for new startups; so early stage is one dimension. We like to help shape the company at the earliest stages. Secondly, we like to invest in difficult technologies, which usually means they are unique and have very little competition. As such patents, although helpful, are not what we particularly look for - we would rather we see the potential for a business-technology 'moat' combination irrespective of any patent position. Thirdly, the product, technology and team must have strong science and/or computational components. An ideal team would be recent doctoral graduates combined with seasoned industrialists who get along with each other.

We cover longevity in a wide context - i.e. beyond rejuvenation technologies, what areas do you categorise as longevity?

Yes, we have the same view; there will be many societal impacts and there will be many different products other than biotech. These could be robots (helpers or companions), self-driving vehicles, workplace marketplaces, or telecommunications enhancers to allow for at home-work interactivity. For example when developing products for the disabled the products then will be used by a wider audience. Previously texting as a communication method allowed mobile phone makers to enable communication with deaf people, yet it turned out that this functionality was liked and widely used by everybody.

Are there any longevity companies that you've invested in that would be of interest to our readers?

There is a macro trend of increasing computation capability, both in terms of computer processing speed and increased availability of medical data. Healx.ai is trying to speed up the production of drugs by a factor of 20, and also reduce the cost of drug discovery by a factor of 20. The initial targets are diseases, but one would expect that hundreds of treatments could be created at a fraction of a cost of traditional methodologies. Another one is Exonate which has a treatment for macular degeneration - the normal treatment requires an injection into the eye which is not very pleasant for the patient or the doctor. Exonate is working on an eye drop and has a strategic arrangement with Janssen.

Comments

It would be nice if the VC community or SENSRF/Methuselah would now turn to antiviral therapies. I'm sure they would be of much greater interest now with COVID-19. The research apparently stopped on DRACO back in 2015.
https://en.wikipedia.org/wiki/DRACO

Posted by: Morpheus at March 23rd, 2020 5:23 PM

Shouldn't we be talking about how the current pandemic will affect funding and ETA of therapies? I imagine that the recession (or depression) that will follow this disaster will slow everything down, but I do wonder if a hightened awareness of group mortality will create more interest in preventing death by aging too.

Posted by: Barbara T. at March 23rd, 2020 8:34 PM

I was wondering when someone was going to comment on this huge (and very scary) situation. At least we have a great leadership in California(NOPE, not the president)

I was wondering also how far back LEV is held back due to this virus.

And, REALLY wish Reason was much further along in his company. We definitely need some way to greatly boost our immunity system (at least for some of us older people)

Everyone, please practice health safety in this situation. And, as my wife often says when I'm driving, keep distance.

Posted by: Robert at March 23rd, 2020 10:31 PM

I was just concerned that new flu viruses randomly emerge like H1N1 in 2009 which was much milder. You also hear of reports of periodic Ebola outbreaks. If LEV is going to take at least another 15+ years, there is a fair chance of another really bad outbreak like this one shutting down the global economy. If somebody out there has a ingenious solution, the savings to mankind would be tremendous. An improved antiviral treatment would be a downstream treatment for the elderly.

Posted by: Morpheus at March 23rd, 2020 10:53 PM

I know FA! runs on the policy of not caring about stuff that a lot of people passionatly care about.
But it still feels weird not to take this chance: What chance? I don't know, I'm a loser compared to Reason, thats why I come here to read his mind.

Can we get one post on this issue?

Burn FDA
Fund anti viral research
Pulmonary fibrosis breaking
Cryo for those who wont make it
Antioxidant therapy for people on life support
Make normal people clean up their act and care about life science

Posted by: arren brandt at March 24th, 2020 12:05 AM

Alzforum is requesting researchers to comment on how this covid hysteria shutdown is affecting their research (albeit they don't use that wording).

Posted by: Antonio at March 24th, 2020 1:39 PM

Are there ways for small individual investors to take a position in startups like these?

Posted by: Matthew Jamison at March 24th, 2020 4:09 PM

"we are amidst something of a hysteria regarding all things viral". Thanks, Reason. Please, talk more about it. Until now, I was feeling alone in my position. The rejuvenation community could do better, and not just follow the masses immersed in the paradigm of aging acceptance.

Posted by: Nicolas Chernavsky at March 24th, 2020 10:41 PM

The average mortality in the region of Italy struck increased by a lot. Same newspaper would carry two pages obituaries in early february now carry 12 pages. IIRC the avg. mortality was up by four times in some regions.

The average accumulated damage which we care about, is probably not even being reported most of the time, but with this virus even doctors are forced to admit that many patients have devastating decrease in lung function. Pulmonary fibrosis etc probably.

Posted by: arren brandt at March 26th, 2020 12:31 AM

It's real, I am here, quarantined at home for 14 days. Hospitals, morgues, crematories are overwhelmed. Monthly deaths have more than trebled. This is not hysteria, unless one can define grief at the potential loss of millions within a few months as a hysteric reaction.

Aside from the immediate problem (which btw is worse for the aged), I think that ignoring how this will impact future R&D funding and priorities amounts to burying one's head in the sand.

Posted by: Barbara T. at March 26th, 2020 1:51 PM

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.